• Dr. Chand Khanna | Comparative Oncology 2.0

  • Sep 15 2024
  • Duración: 38 m
  • Podcast

Dr. Chand Khanna | Comparative Oncology 2.0

  • Resumen

  • In this episode of the Veterinary Cancer Pioneers Podcast, Dr. Rachel Venable is joined by Dr. Chand Khanna, founder and board chair of Ethos Discovery, to explore the advancements in comparative oncology. Dr. Khanna delves into the concept of Comparative Oncology 2.0, discussing the increasing collaboration between human and animal health companies. They also examine the challenges of clinical trials, regulatory hurdles, and the future potential of comparative oncology in accelerating cancer drug development. Dr. Khanna highlights key examples of successful transactions between animal health and biotech companies. The conversation reveals how veterinary oncology can significantly contribute to human cancer treatment breakthroughs. Tune in for a deep dive into cutting-edge veterinary cancer research.

    • Citation mentioned in the episode: Fenger JM, Eward W, Hendricks W, McNiel E, Johannes C, et al. (2020) Delivering Innovation to Oncology Drug Development Through Cancer Drug DISCO (Development Incentive Strategy using Comparative Oncology): Perspectives, Gaps and Solutions. Ann med clin Oncol 3: 120. DOI: 10.29011/AMCO-120.000120 (https://www.gavinpublishers.com/article/view/delivering-innovation-to-oncology-drug-development-through-cancer-drug-disco-development-incentive-strategy-using-comparative-oncology-perspectives-gaps-and-solutions)

    📝Transcripts are available at https://www.imprimedicine.com/podcast.

    To learn more about ImpriMed Personalized Prediction Profile, please visit https://www.imprimedicine.com/personalized-prediction-profile

    Music Credit: Hazy by Beat Mekanik

    Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Dr. Chand Khanna | Comparative Oncology 2.0

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.